Natriuretic Peptides as Regulators of Myocardial Structure and Function: Pathophysiologic and Therapeutic Implications

Heart Failure Clinics

Volumn 2, Issue 3, 2006, Pages 269-276

  Cataliotti, Alessandro ^a   Chen, Horng H ^a   Redfield, Margaret M ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CONJUGATED HUMAN BRAIN NATRIURETIC PEPTIDE; DENDROASPIS NATRIURETIC PEPTIDE; DIURETIC AGENT; MACROGOL; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; OLIGOMER; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; ENDOCRINE FUNCTION; ENDOCRINE SYSTEM; FIBROBLAST; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW;

CARDIOVASCULAR DISEASES; FIBROBLASTS; HEART; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDES;

EID: 33750827795     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2006.09.002     Document Type: Review

References (38)

1. Garbers D.L., Chrisman T.D., Wiegn P., et al. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab 17 6 (2006) 251-258
2. Cameron V.A., and Ellmers L.J. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinology 144 6 (2003) 2191-2194
3. Lopez M.J., Wong S.K., Kishimoto I., et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378 6552 (1995) 65-68
4. Oliver P.M., Fox J.E., Kim R., et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94 26 (1997) 14730-14735
5. Holtwick R., van Eickels M., Skryabin B.V., et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 9 (2003) 1399-1407
6. Lainchbury J.G., Burnett Jr. J.C., Meyer D., et al. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 278 1 (2000) H33-H40
7. Chinkers M., and Garbers D.L. The protein kinase domain of the ANP receptor is required for signaling. Science 245 4924 (1989) 1392-1394
8. Patel J.B., Valencik M.L., Pritchett A.M., et al. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 289 2 (2005) H777-H784
9. Tokudome T., Horio T., Kishimoto I., et al. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation 111 23 (2005) 3095-3104
10. Silberbach M., Gorenc T., Hershberger R.E., et al. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem 274 35 (1999) 24858-24864
11. Kato T., Muraski J., Chen Y., et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 115 10 (2005) 2716-2730
12. Cameron V.A., Rademaker M.T., Ellmers L.J., et al. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology 141 12 (2000) 4690-4697
13. Tsuruda T., Boerrigter G., Huntley B.K., et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 12 (2002) 1127-1134
14. Calderone A., Bel-Hadj S., Drapeau J., et al. Scar myofibroblasts of the infarcted rat heart express natriuretic peptides. J Cell Physiol 207 1 (2006) 165-173
15. Kapoun A.M., Liang F., O'Young G., et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94 4 (2004) 453-461
16. Huntley B.K., Sandberg S.M., Noser J.A., et al. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol 9999 (2006) 1-7
17. Tamura N., Ogawa Y., Chusho H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97 8 (2000) 4239-4244
18. Hawkridge A.M., Heublein D.M., Bergen III H.R., et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102 48 (2005) 17442-17447
19. Belluardo P., Cataliotti A., Bonaiuto L., et al. Lack of activation of the molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol 291 4 (2006) H1529-H1535
20. Dries D.L., Victor R.G., Rame J.E., et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 112 16 (2005) 2403-2410
21. Chan J.C., Knudson O., Wu F., et al. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA 102 3 (2005) 785-790
22. Rubattu S., Bigatti G., Evangelista A., et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48 3 (2006) 499-505
23. Deschepper C.F. The many possible benefits of natriuretic peptides after myocardial infarction. Hypertension 46 2 (2005) 271-272
24. Michaels A.D., Klein A., Madden J.A., et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 107 21 (2003) 2697-2701
25. Cataliotti A., Boerrigter G., Costello-Boerrigter L.C., et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 109 13 (2004) 1680-1685
26. Ito T., Yoshimura M., Nakamura S., et al. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 107 6 (2003) 807-810
27. Brunner-La Rocca H.P., Kaye D.M., Woods R.L., et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 37 5 (2001) 1221-1227
28. Yamahara K., Itoh H., Chun T.H., et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 100 6 (2003) 3404-3409
29. Hayashi M., Tsutamoto T., Wada A., et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37 7 (2001) 1820-1826
30. Wang W., Ou Y., and Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 21 11 (2004) 2105-2111
31. Cataliotti A., Schirger J.A., Martin F.L., et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 112 6 (2005) 836-840
32. Schweitz H., Vigne P., Moinier D., et al. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 267 20 (1992) 13928-13932
33. Best P.J., Burnett J.C., Wilson S.H., et al. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 55 2 (2002) 375-384
34. Lisy O., Jougasaki M., Heublein D.M., et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 56 2 (1999) 502-508
35. Singh G., Kuc R.E., Maguire J.J., et al. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 99 2 (2006) 183-190
36. Margulies K.B., and Burnett Jr. J.C. Visualizing the basis for paracrine natriuretic peptide signaling in human heart. Circ Res 99 2 (2006) 113-115
37. Chen H.H., Lainchbury J.G., and Burnett Jr. J.C. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 40 6 (2002) 1186-1191
38. Lisy O., Lainchbury J.G., Leskinen H., et al. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 37 4 (2001) 1089-1094